Management strategies for cardiogenic shock

Current Opinion in Cardiology

Volumn 19, Issue 6, 2004, Pages 608-612

  Sanborn, Timothy A ^a,b   Feldman, Ted ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b EVANSTON NORTHWESTERN HEALTHCARE   (United States)

Author keywords

Acute myocardial infarction; Bypass surgery; Cardiogenic shock; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; DOBUTAMINE; DOPAMINE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; N(G) METHYLARGININE; N(G) NITROARGININE METHYL ESTER;

ACUTE HEART INFARCTION; AGE; AORTA BALLOON; CARDIOGENIC SHOCK; CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; CORONARY STENT; COUNTERPULSATION; CRITICAL ILLNESS; DRUG EFFICACY; EMERGENCY HEALTH SERVICE; EMERGENCY SURGERY; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE REVASCULARIZATION; HEART VENTRICLE SEPTUM RUPTURE; HUMAN; INCIDENCE; MITRAL VALVE REGURGITATION; MORTALITY; PATHOPHYSIOLOGY; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; HUMANS; LIFE SUPPORT SYSTEMS; SHOCK, CARDIOGENIC; SURVIVAL RATE;

EID: 8344257208     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hco.0000142064.30214.1c     Document Type: Review

References (36)

1. Leor J, Goldbourt U, Reicher-Reiss H, et al. Cardiogenic shock complicating acute myocardial infarction in patients without heart failure on admission: incidence, risk factors, and outcome. SPRINT Study Group. Am J Med 1993, 94:265-273.
2. Holmes DR Jr, Bates ER, Kleiman NS, et al.: Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1995, 26:668-674.
3. Goldberg RJ, Samad NA, Yarzebski J, et al.: Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med 1999, 340:1162-1168.
4. Hasdai D, Holmes DR Jr, Topol EJ, et al.: Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase and alteplase: requests from GUSTO III. Eur Heart J 1999, 20:128-135.
5. Holmes DR Jr, Berger PB, Hochman JS, et al.: Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. Circulation 1999, 100:2067-2073.
6. Lindholm MG, Kober L, Boesgaard S, et al.: Cardiogenic shock complicating acute myocardial infarction. Eur Heart J 2003, 24:258-265. This large nationwide registry discusses the incidence and timing of cardiogenic shock complicating acute MI.
7. Jacobs AK, French JK, Col J, et al.: Cardiogenic shock with non-ST-segment elevation myocardial infarction: a report from the SHOCK Trial Registry. Should we emergently revascularize occluded coronaries for cardiogenic shock? J Am Coll Cardiol 2000, 36:1091-1096.
8. Hochman JS, Sleeper LA, Webb JG, et al.: Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock? N Engl J Med 1999, 341:625-634.
9. Goldberg RJ, Gore JM, Thompson CA, et al.: Recent magnitude of and temporal trends (1997-1997) in the incidence and hospital death rates of cardiogenic shock complicating acute myocardial infarction: the Second National Registry of Myocardial Infarction. Am Heart J 2001, 141:65-72.
10. Webb JG, Sleeper LA, Buller CE, et al.: Implications of the timing of onset of cardiogenic shock after acute myocardial infarction: a report from the SHOCK trial Registry. Should we emergently revascularize occluded coronaries for cardiogenic shock? J Am Coll Cardiol 2000, 36:1084-1090.
11. Hochman JS, Buller CE, Sleeper LA, et al.: Cardiogenic shock complicating acute myocardial infarction: etiologies, management and outcome: a report from the SHOCK Trial Registry. Should we emergently revascularize occluded coronaries for cardiogenic shock? J Am Coll Cardiol 2000, 36:1063-1070.
12. AIMS Trial Study Group: Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo controlled clinical trial. Lancet 1988, i:545-549.
13. Wilcox RG, van der Lippe G, Olsson CG, et al.: Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988, 1:525-530.
14. Barron HV, Every NR, Parsons LS, et al.: The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: data from the National Registry of Myocardial Infarction 2. Am Heart J 2001, 141:933-939.
15. Sanborn TA, Sleeper LA, Bates ER, et al.: Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. Should we emergently revascularize occluded coronaries for cardiogenic shock? J Am Coll Cardiol 2000, 36:1123-1129.
16. Anderson RD, Ohman EM, Holmes DR Jr, et al.: Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I Study. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol 1997, 30:708-715.
17. Ryan TJ, Antman EM, Brooks NH, et al.: Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice (Committee on Management of Acute Myocardial Infarction) Guidelines. Circulation 1999, 100:1016-1030.
18. Hudson MP, Granger CB, Stebbins A, et al.: Cardiogenic shock survival and use of intra anti balloon counterpulsation: results from the GUSTO I and III trials. Circulation 1999, 100:I-370.
19. Thiele H, Lauer B, Boudroit E, et al.: Reversal of cardiogenic shock by left atrial-to-femoral arterial bypass assistance. Circulation 2001, 104:2917-2922.
20. Smalling RW, Sweeney M, Lachterman B, et al.: Transvalvular left ventricular assistance in cardiogenic shock secondary to acute myocardial infarction: evidence for recovery from near fatal myocardial stunning. J Am Coll Cardiol 1994, 23:637-644.
21. Kurose M, Okamoto K, Sato T, et al.: Emergency and long term extracorporeal life support following acute myocardial infarction: rescue from severe cardiogenic shock related to stunned myocardium. Clin Cardiol 1994, 17:552-557.
22. Lane GE, Holmes DR: The modern strategy for cardiogenic shock. In: Cannon CP, ed. Management of Acute Coronary Syndromes. Totowa, NJ: Humana Press; 2003:603-651.
23. Edep ME, Brown DL: Effect of early revascularization in mortality from cardiogenic shock complicating acute myocardial infarction in California. Am J Cardiol 2000, 85:1185-1188.
24. Hochman JS, Sleeper LA, White HD, et al.: One-year survival following early revascularization for cardiogenic shock. JAMA 2001, 285:190-192.
25. Ryan TJ, Antman EM, Brooks NH, et al.: Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1999, 34:890-911.
26. Dzavik V, Sleeper LA, Cocke TP, et al.: Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the Shock Trial Registry. Eur Heart J 2003, 24:828-837. In this report from the SHOCK Trial Registry, covariate-adjusted modeling revealed that elderly patients selected for early revascularization have a lower mortality rate than those receiving a revascularization procedure later or never.
27. Prasad A, Lennon RJ, Rihal CS, et al.: Outcomes of elderly patients with cardiogenic shock treated with early percutaneous revascularization. Am Heart J 2004, 147:1066-1077.
28. Dauerman HL, Ryan TJ, Winthrop WD, et al.: Outcomes of percutaneous coronary intervention among elderly patients in cardiogenic shock: a multicenter, decade-long experience. J Invas Cardiol 2003, 15:380-384. The authors suggest that real-world selection of elderly shock patients for PCI is possible, with mortality rates far less than that seen in earlier randomized trials.
29. Al Suwaidi J, Berger PB, Holmes DR: Coronary artery stents. JAMA 2000, 284:1828-1836.
30. Wilson SH, Bell MR, Rihal CS, et al.: Infarct reocclusion after primary angioplasty, stent placement and thrombolytic therapy for acute myocardial infarction. Am Heart J 2001, 141:704-710.
31. Hasdai D, Topol EJ, Califf RM, et al.: Cardiogenic shock complicating acute coronary syndromes. Lancet 2000, 356:749-756.
32. Webb JG, Sanborn TA, Sleeper LA, et al.: Percutaneous coronary intervention for cardiogenic shock in the SHOCK Trial Registry. Am Heart J 2001, 141:964-970.
33. Stone GW, Grines CL, Cox DA: The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting with or without abciximab in acute myocardial infarction. N Engl J Med 2002, 346:957-966.
34. Webb JG, Sanborn T, Carere RG, et al.: Coronary stenting in the SHOCK trial. Circulation 1999, 100:1-87.
35. Chan AW, Chen DP, Bhatt DL, et al.: Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction. Am J Cardiol 2002, 89:132-136.
36. Cotter G, Kaluski E, Blatt A, et al.: L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. Circulation 2000, 101:1358-1361.